The effects of laropiprant on the antiplatelet activity of co-administered clopidogrel and aspirin

Platelets

Volumn 25, Issue 7, 2014, Pages 480-487

  De Kam, Pieter Jan ^a   Luo, Wen Lin ^a   Wenning, Larissa ^a   Ratcliffe, Lisa ^a   Sisk, Christine McCrary ^a   Royalty, Jane ^b   Radziszewski, Waldemar ^a   Wagner, John A ^a   Lai, Eseng ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Formerly Merck and Co Inc ^*  (United States)

Author keywords

Aspirin; Clopidogrel; Laropiprant; Pharmacokinetics

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; LAROPIPRANT; LAROPIPRANT PLUS NICOTINIC ACID; PLACEBO; ANTITHROMBOCYTIC AGENT; INDOLE DERIVATIVE; MK-0524; TICLOPIDINE;

ABDOMINAL DISCOMFORT; ABDOMINAL DISTENSION; ADULT; ALOPECIA; ANTICOAGULATION; AREA UNDER THE CURVE; ARTICLE; BACKACHE; BLEEDING; BLEEDING TIME; BLEPHARITIS; CLINICAL ARTICLE; COLD SWEAT; COMPLICATION; CONSTIPATION; CONTACT DERMATITIS; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY EYE; DRY NOSE; DRY THROAT; DYSLIPIDEMIA; DYSPEPSIA; ECCHYMOSIS; EPISTAXIS; FEMALE; FLATULENCE; FOLLICULITIS; GASTROENTERITIS; GINGIVA BLEEDING; HEMATOMA; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; JAW PAIN; JOINT SWELLING; LIMB PAIN; MALE; MAXIMUM PLASMA CONCENTRATION; MYALGIA; NAUSEA AND VOMITING; NECK PAIN; NOSE OBSTRUCTION; OUTCOME ASSESSMENT; PARESTHESIA; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SKIN BLEEDING; SKIN INJURY; SOMNOLENCE; STEADY STATE; THROMBOCYTE AGGREGATION; THROMBOCYTE RICH PLASMA; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; VASODILATATION; VISUAL IMPAIRMENT; XEROSTOMIA; AGED; ANALOGS AND DERIVATIVES; BLOOD; DRUG INTERACTION; DYSLIPIDEMIAS; METABOLISM; MIDDLE AGED; YOUNG ADULT;

ADULT; AGED; ASPIRIN; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; DYSLIPIDEMIAS; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; INDOLES; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE; YOUNG ADULT;

EID: 84911996318     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.3109/09537104.2013.836747     Document Type: Article

References (20)

1. Chang SW, Reddy V, Pereira T, Dean BJ, Xia YQ, Seto C, Franklin RB, Karanam BV. The pharmacokinetics and disposition of MK-0524, a Prosglandin D2 Receptor 1 antagonist, in rats, dogs and monkeys. Xenobiotica 2007;37:514-533
2. Levesque JF, Day SH, Chauret N, Seto C, Trimble L, Bateman KP, Silva JM, Berthelette C, Lachance N, Boyd M, et al. Metabolic activation of indole-containing prostaglandin D2 receptor 1 antagonists: Impacts of glutathione trapping and glucuronide conjugation on covalent binding. Bioorg Med Chem Lett 2007;17: 3038-3043
3. Sturino CF, ONeill G, Lachance N, Boyd M, Berthelette C, Labelle M, Li L, Roy B, Scheigetz J, Tsou N, et al. Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1, 2, 3, 4-Tetra hydrocy clopenta[b]indol-3-yl]-Acetic acid (MK-0524). J Med Chem 2007;50:794-806
4. Lai E, De I L, Crumley TM, Liu F, Wenning LA, Michiels N, Vets E, ONeill G, Wagner JA, Gottesdiener K. Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subtype 1. Clin Pharmacol Ther 2007;81:849-857
5. Paolini JF, Mitchel YB, Reyes R, Kher U, Lai E, Watson DJ, Norquist JM, Meehan AG, Bays HE, Davidson M, et al. Effects of laropiprant on nicotinic Acid-induced flushing in patients with dyslipidemia. Am J Cardiol 2008;101:625-630
6. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994;330: 1287-1294
7. Jane Armitage on behalf of the HPS2-THRIVE Collaborative Group, HPS2-THRIVE: Randomized placebo-controlled trial of ER niacin and laropiprant in 25, 673 patients with pre-existing cardiovascular disease. Presented at American College of Cardiology-ACC 2013
8. Merck, Results from HPS2-THRIVE Study of TREDAPTIVE-(extended-release niacin/laropiprant) Presented at American College of Cardiology Scientific Sessions [press release]. San Francisco, CA 2013
9. Song WL, Stubbe J, Ricciotti E, Alamuddin N, Ibrahim S, Crichton I, Prempeh M, Lawson JA, Wilensky RL, Rasmussen LM, et al. Niacin and biosynthesis of PGD(2) by platelet COX-1 in mice and humans. J Clin Invest 2012;122:1459-1468
10. Philipose S, Konya V, Lazarevic M, Pasterk LM, Marsche G, Frank S, Peskar BA, Heinemann A, Schuligoi R. Laropiprant attenuates EP3 and TP prostanoid receptor-mediated thrombus formation. PLoS One 2012;7:e40222
11. Gresele P, Deckmyn H, Nenci GG, Vermylen J. Thromboxane synthase inhibitors, thromboxane receptor antagonists and dual blockers in thrombotic disorders. Trends Pharmacol Sci 1991;12: 158-163
12. Lai E, Schwartz JI, Dallob A, Jumes P, Liu F, Kraft WK, Royalty J, Chodakewitz JA, McCrary Sisk C, Radziszewski W, et al. Effects of extended release niacin/laropiprant, laropiprant, extended release niacin and placebo on platelet aggregation and bleeding time in healthy subjects. Platelets 2010;21: 191-198
13. Dallob A, Luo WL, Luk JM, Ratcliffe L, Johnson-Levonas AO, Schwartz JI, Dishy V, Kraft WK, De Hoon JN, Van Hecken A, et al. The effects of laropiprant, a selective prostaglandin D(2) receptor 1 antagonist, on the antiplatelet activity of clopidogrel or aspirin. Platelets 2011;22:495-503
14. Savi P, Nurden P, Nurden AT, Levy-Toledano S, Herbert JM. Clopidogrel: A review of its mechanism of action. Platelets 1998;9: 251-255
15. Buchanan GR, Holtkamp CA. A comparative study of variables affecting the bleeding time using two disposable devices. Am J Clin Pathol 1989;91:45-51
16. Cattaneo M. Aspirin and clopidogrel: Efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol 2004;24: 1980-1987
17. Mangin P, Ohlmann P, Eckly A, Cazenave JP, Lanza F, Gachet C. The P2Y1 receptor plays an essential role in the platelet shape change induced by collagen when TxA2 formation is prevented. J Thromb Haemost 2004;2:969-977
18. Lauring B, Dishy V, Luo WL, Laterza O, Patterson J, Cote J, Chao A, Larson P, Gutierrez M, Wagner JA, et al. Laropiprant in combination with extended-release niacin does not alter urine 11-dehydrothromboxane B2, a marker of in vivo platelet function, in healthy, hypercholesterolemic, and diabetic subjects. J Clin Pharmacol 2009;49:1426-1435
19. Dearing BD, Lavie CJ, Lohmann TP, Genton E. Niacin-induced clotting factor synthesis deficiency with coagulopathy. Arch Intern Med 1992;152:861-863
20. AbbVie Inc., Niaspan Prescribing Information. Available at: http://www.rxabbvie.com/pdf/niaspan.pdf. Accessed August 13, 2013